KU Leuven enters international licence agreement on cancer therapy
KU Leuven enters international licence agreement on cancer therapy These updates are republished press releases and communications from members of the Science|Business Network TEAD inhibition holds great promise as a therapeutic approach as the Hippo pathway is genetically altered in up to 10% of cancers. In mesothelioma, an aggressive and untreatable cancer often caused by asbestos exposure, 60 to 70% of patients have mutations in the Hippo pathway leading to striking sensitivity to TEAD-inhibitors. SpringWorks Expects to Nominate a Development Candidate and Commence IND-E...
Source: sciencebusiness.net